ERBB2 and neoplasm: Studies indicate that HER2-low TNBC patients feature more aggressive tumor characteristics than the HER2-null phenotype, including larger tumor size, frequent lymph nodes involvement, higher grade and a worse prognosis (HR [CI 95%] =3.44) with an adverse immune microenvironment [50, 51].